- Appili Therapeutics (TSXV:APLI) has announced the appointment of Dr. Yoav Golan as the company’s Chief Medical Officer
- Dr. Golan has spent more than 25 years as an infectious disease medical specialist
- In his role, he will be responsible for the clinical development strategy and execution across Appili’s pipeline of assets
- Initially, Dr. Golan will split his time between Appili and his role as a professor at Tufts University School of Medicine in Boston
- Appili Therapeutics (APLI) is currently down 7.34 per cent to C$1.01 per share, with a market cap of $46.87 million
Appili Therapeutics (TSXV:APLI) has announced the appointment of Dr. Yoav Golan as the company’s Chief Medical Officer.
Dr. Golan has spent more than 25 years as an infectious disease medical specialist.
He currently serves as an associate professor at Tufts University School of Medicine in Boston, and previously acted as an attending physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center.
Over the course of his career, Dr. Golan has conducted extensive research in the infectious diseases space. He has also published several books, as well as more than 50 peer-reviewed studies in leading journals such as The New England Journal of Medicine and The Lancet Infectious Diseases.
His research has focussed primarily on hospital-acquired infections, with an emphasis on ICU infections and the impact of antibiotic resistance. Dr. Golan has subsequently been involved in the development of several anti-invectives, including fidaxomicin, ceftaroline and bezlotuximab.
Armand Balboni, CEO of Appili Therapeutics, said he is thrilled to have an executive of Yoav’s calibre on board.
“As Appili’s pipeline assets progress toward active clinical trials, and our focus expands to include multiple types of antimicrobial programs, now is the optimal time to add patient-centered medical expertise to our leadership team,” he said.
In his role as Chief Medical Officer, Dr. Golan will be responsible for the clinical development strategy and execution of Appili’s growing asset pipeline and lead the company’s clinical programs.
Commenting on his appointment, Dr. Golan noted that strong and viable solutions are needed to address the increasing effect of emerging infections.
“Appili is doing excellent work to advance critical programs in the infectious disease space, and I look forward to continued work with the Board and the company’s leadership team to advance research and help the patients who need better anti-infective options,” he said.
In the early stages of his role, Dr. Golan will split his time between requirements at Appili and his commitments at Tufts University School of Medicine.
Appili Therapeutics (APLI) is currently down 7.34 per cent to C$1.01 per share at 1:43pm EST.
